Man resting among an imagined orchestra, with two identical tuning forks on a nearby table.
Back to the library

Energy & sleep

Alpha-Stim and cranial electrotherapy stimulation

Cranial electrotherapy stimulation passes a tiny alternating current through earclip electrodes, and Alpha-Stim is the most studied device. A 2014 double-blind trial of 115 people reported large reductions in anxiety and depression over sham, but a 2018 systematic review of 26 trials rated the evidence low-strength at best, and the largest independent trial, a 236-person NHS study published in The Lancet Psychiatry in 2023, found active Alpha-Stim no more effective than sham for depression. The device appears safe; whether it outperforms placebo remains unproven.

Evidence so far
Early
Reading timeAbout 12 minutes

Start here

Why this is being studied

Cranial electrotherapy stimulation (CES) delivers a sub-sensory current, usually 100 to 500 microamps at around 0.5 Hz, through clips on the earlobes for 20 to 60 minutes at a time. Alpha-Stim, a US-made device cleared for anxiety, insomnia and pain, has been trialled in NHS services and is marketed as a drug-free option. It is studied because anxiety, low mood, poor sleep and persistent pain share overlapping arousal circuitry, and because a low-risk home device would be valuable if it worked. For members the honest position is that it is safe and some people find the routine calming; for clinicians the key facts are a positive but unregistered single-site trial, a cautious independent systematic review, and a large publicly funded UK trial that was negative.

Where the evidence stands

Flag text

The mechanism

What is going on, and why this might help

What is going on in the body

Anxiety, low mood, poor sleep and persistent pain share a lot of underlying biology. The brain's threat and arousal circuits stay switched on for longer than is useful, the balance between the sympathetic (alerting) and parasympathetic (settling) branches of the autonomic nervous system tips towards alert, and the electrical rhythms measured on an EEG shift away from the relaxed alpha range towards faster, more vigilant patterns. Over time this state feeds back on itself: poor sleep worsens anxiety, anxiety heightens pain perception, and pain disrupts sleep. Most treatments, whether talking therapy, medication or breathing practice, are ultimately trying to reset this loop.

Where the current comes in

Cranial electrotherapy stimulation delivers a very small alternating current, typically 100 to 500 microamps at around 0.5 Hz, through clips on the earlobes. Alpha-Stim is the most widely studied device and the one used in the UK NHS trial. The current is below the level most people can feel. The proposed mechanism is that a fraction of it reaches the brainstem, thalamus and limbic structures and shifts their firing towards a calmer pattern, which its makers describe as an increase in alpha-band EEG activity and changes in neurotransmitters such as serotonin and endorphins. Modelling studies suggest that some current does reach deep structures at low intensity, but direct human evidence for the neurochemical claims is thin, and it is not clear how much of any effect is due to the current itself and how much to sitting quietly for an hour with a device that is expected to help.

How solid is this

Honestly, it is contested. A 2014 double-blind trial of 115 people with anxiety and depression, run in private practice with no funding, reported large benefits over sham on both anxiety and depression scales. A 2018 systematic review for the US Veterans Health Administration in Annals of Internal Medicine looked at 26 randomised trials and found only low-strength evidence of a modest benefit for anxiety with co-existing depression, and insufficient evidence for depression alone, insomnia or pain, with every trial judged at high risk of bias. Then in 2023 the largest and most independent trial to date, a 236-person NHS-funded double-blind study in English primary care published in The Lancet Psychiatry, found that active Alpha-Stim was safe and well tolerated but no more effective than an identical sham device for depression. The fair summary is that the device is low-risk, that some people report feeling calmer using it, and that the best-designed evidence has not shown it to beat placebo.

Explainer illustration

The studies

Every study is laid out the same way: what the researchers wanted to find out, who took part, what they actually did, what they found, why it might work and where the limits are. No jargon, and a link to the original if you want to read it yourself.

Each study is laid out the same way: what the researchers asked, who took part, what they did, what they found, why it might work, and where the limits are. The clinician layer at the end of each one carries the numbers.

Paper 1

A clinical trial of cranial electrotherapy stimulation for anxiety and comorbid depression

Barclay et al. · Journal of Affective Disorders · 2014 · Randomised double-blind sham-controlled trial, n=115

Read the paper

What they asked

Anxiety disorders very often come packaged with depression, and the combination is harder to treat than either alone. Medication and talking therapies work for many people but not all, and some prefer to avoid drugs. Cranial electrotherapy stimulation had been sold in the United States for decades, but most of the supporting studies were small, old or open-label. Timothy and Raymond Barclay, working in a private practice setting, set out to run a properly powered, randomised, double-blind, sham-controlled trial to answer a straightforward question: over five weeks of daily use, does an active Alpha-Stim device reduce anxiety and depression symptoms more than an identical-looking device that delivers no current?

Who took part

One hundred and fifteen adults were enrolled, all with a primary anxiety disorder and depressive symptoms that met criteria for a comorbid diagnosis. They were recruited from a private practice population rather than a hospital or research centre, which means they were probably somewhat more motivated and less severely unwell than people seen in secondary care. Participants were randomly allocated so that 57 received an active device and 51 a sham device, and 108 of the 115 completed the trial, a good retention rate for a five-week daily programme. The two groups were similar on baseline anxiety and depression scores, which matters because it means later differences are less likely to be due to chance imbalance at the start.

What they did

Every participant took home a device and used it for sixty minutes each day for five weeks, with ear-clip electrodes. The active devices delivered a current of 100 microamps, which is below the level most people can feel. The sham devices were identical in appearance and operation but conducted no current. Neither the participants nor the clinicians rating them knew who had which. Anxiety was measured with the Hamilton Anxiety Rating Scale and depression with the 17-item Hamilton Depression Rating Scale, both rated by a clinician, at the start and at the end of the five weeks. A response was defined as at least a 50 per cent fall in score. Statistical analysis adjusted for baseline scores.

What they found

The active group's anxiety scores fell by about 16 points, roughly a 55 per cent improvement, compared with about 8 points or 27 per cent in the sham group. Depression scores fell by about 8 points, again around 55 per cent, against about 3 points or 24 per cent with sham. Both differences were statistically significant with p values of 0.001, and the effect sizes were large for anxiety (Cohen's d 0.94) and moderate to large for depression (d 0.78). Around 83 per cent of the active group met the response threshold for anxiety and 82 per cent for depression. No adverse events were reported. It is worth noticing that the sham group also improved substantially, which is typical in anxiety and depression trials.

Why it might work

The device's proposed mechanism is that a small fraction of the sub-sensory current reaches the brainstem and limbic structures involved in arousal and mood, nudging their electrical rhythms towards a calmer, alpha-dominant pattern and shifting neurotransmitter balance. EEG studies with similar devices have reported increases in alpha activity and decreases in faster beta activity during stimulation. It is also plausible that a daily hour of sitting quietly with a device that is expected to help acts as a structured wind-down ritual, which on its own can reduce anxiety. The sham arm was designed to control for that second explanation, and the size of the gap between groups is what makes this trial notable.

Limits

This was a single-site study run by two clinicians who also authored it, with no independent oversight or trial registration reported. Outcomes were assessed at five weeks only, so nothing is known about whether benefits lasted. Because the current is sub-sensory, blinding is in principle good, but the paper does not report a test of whether participants guessed their allocation. The effect sizes are large by the standards of the field, larger than most drug trials achieve, which invites the question of why later, bigger and more independent trials have not reproduced them. The authors reported no conflicts of interest and no funding, which is reassuring but does not remove the issues of a single small unregistered trial.

Paper 2

Clinical effectiveness of active Alpha-Stim AID versus sham Alpha-Stim AID in major depression in primary care in England (Alpha-Stim-D): a multicentre, parallel group, double-blind, randomised controlled trial

Morriss et al. · The Lancet Psychiatry · 2023 · Multicentre double-blind randomised sham-controlled trial, n=236

Read the paper

What they asked

By the early 2020s Alpha-Stim was being offered in some NHS services and promoted as a drug-free option for anxiety and depression, largely on the strength of smaller trials like the Barclay study and an open-label NHS pilot. What was missing was a large, independent, publicly funded trial in the kind of setting where the device would actually be used. Richard Morriss and colleagues at the University of Nottingham asked whether eight weeks of daily active Alpha-Stim, added to usual GP care, would reduce depressive symptoms more than an identical sham device in adults with moderate depression seen in English primary care, and whether it was safe and acceptable enough to recommend for wider NHS use.

Who took part

Two hundred and thirty-six adults were recruited from 25 general practices across England. All had a current diagnosis of major depression with symptoms in the moderate range, scoring between 10 and 19 on the PHQ-9 questionnaire. Many had tried antidepressants or talking therapy before, and they continued whatever usual care their GP provided during the trial. People with severe depression, psychosis or high suicide risk were excluded, as were those already using a similar device. Participants were randomly assigned one-to-one, 118 to an active device and 118 to a sham, and the groups were well balanced at the start. This is exactly the population a UK wellness member curious about the device is most likely to resemble.

What they did

Each participant used the device at home for sixty minutes a day for eight weeks, with ear-clip electrodes, at a setting of 100 microamps and 0.5 Hz. The sham device was identical in every visible respect, including lights and timers, but delivered no current. Participants, the researchers who assessed them and the statisticians were all blind to allocation. The main outcome was the change in clinician-rated depression on the 17-item GRID Hamilton Depression Rating Scale at 16 weeks, that is eight weeks after the course ended, chosen to capture any lasting effect. Anxiety, quality of life, remission and response rates and adverse events were measured too. The trial was registered in advance (ISRCTN11853110) and funded by the National Institute for Health Research.

What they found

Both groups improved: depression scores fell by about 5.9 points in the active group and 6.5 points in the sham group. The difference between them, 0.6 points in favour of sham, was not statistically significant (p=0.46) and far smaller than anything that would matter to the person using it. Anxiety scores, quality of life, remission and response rates were all similar between groups. Adverse events were uncommon, occurred at about the same rate in both arms (9 versus 8), and were mostly mild headaches. Participants found the device acceptable and used it as instructed. The authors' conclusion was direct: active Alpha-Stim AID was safe and acceptable but no more clinically effective than sham Alpha-Stim AID for major depression in primary care.

Why it might work

The device's rationale rests on the idea that sub-sensory current reaching the brainstem and limbic system can shift arousal circuits towards a calmer state and alter neurotransmitter balance, with alpha-band EEG changes as a proposed marker. This trial did not measure any of that; it measured whether people got better. The striking result is how much the sham group improved. Sixty minutes a day of a structured, restful routine with a device you expect to help, plus continued GP care and the attention of a trial team, appears to have produced most of the benefit that earlier uncontrolled or single-site studies attributed to the current. That does not prove the current does nothing, but it does show that the effect, if any, is too small to detect in a well-run trial of this size.

Limits

The trial studied depression, not anxiety as a primary outcome, although anxiety was a secondary measure and also showed no difference. It excluded people with severe depression, so it cannot speak to that group. Eight weeks of daily use may be less than some proponents recommend. The device manufacturer supplied the devices, though it had no role in design, analysis or reporting, and the trial was publicly funded and independently run. Blinding appears to have held, which matters because a sub-sensory current can be hard to distinguish from no current at all. This trial does not test the device for insomnia or pain. It is, however, the strongest single piece of evidence available on Alpha-Stim in a UK population.

Paper 3

Benefits and harms of cranial electrical stimulation for chronic painful conditions, depression, anxiety, and insomnia: a systematic review

Shekelle et al. · Annals of Internal Medicine · 2018 · Systematic review of 26 randomised controlled trials

Read the paper

What they asked

The US Department of Veterans Affairs was receiving requests to provide cranial electrical stimulation devices to veterans for pain, depression, anxiety, post-traumatic stress and insomnia, and needed to know whether the evidence justified it. It commissioned its Evidence-based Synthesis Program, led by Paul Shekelle at the RAND Corporation and the West Los Angeles VA, to review everything published. The questions were simple: across all randomised trials of any cranial electrical stimulation device, does the treatment work better than sham for each of these conditions, how confident can we be in that answer, and does the treatment cause harm? The review was later published in Annals of Internal Medicine with an accompanying editorial.

Who took part

The review covered 26 randomised controlled trials reported in 28 publications, spanning several decades and several devices, with Alpha-Stim among the most common. Participants ranged from people with fibromyalgia, headache and other chronic painful conditions to those with diagnosed depression, anxiety disorders, insomnia and post-traumatic stress. Many trials were small, often fewer than fifty people, and some dated from the 1970s and 1980s when trial standards were looser. The reviewers also examined observational safety data. Because the trials were so varied in population, device settings and outcome measures, the reviewers were unable to pool them statistically and instead described the evidence for each condition and graded its strength.

What they did

Following a registered protocol, the team searched the major databases and manufacturer bibliographies, screened thousands of records, and included only randomised trials that compared active stimulation against sham or another comparator. Two reviewers independently assessed each trial for risk of bias, looking at randomisation, allocation concealment, blinding, dropouts and selective reporting. They then applied a standard framework to rate the overall strength of evidence for each condition as high, moderate, low or insufficient, taking into account study quality, consistency between trials, directness and precision. Adverse events were tabulated from every included study. The final report was peer-reviewed before publication and made freely available through the National Library of Medicine.

What they found

For anxiety accompanied by depression, the reviewers found low-strength evidence of a possible modest benefit, resting mostly on a small number of trials including the Barclay study. For depression on its own, chronic painful conditions such as fibromyalgia and headache, insomnia and post-traumatic stress, the evidence was rated insufficient to draw any conclusion either way. Every included trial was judged to be at high risk of bias, most often because of doubts about whether participants could tell active from sham, and because of small sample sizes. On safety, there was low-strength evidence that cranial electrical stimulation does not cause serious side effects; reported problems were mild, such as skin irritation at the electrodes, headache or dizziness.

Why it might work

The review noted that the mechanism remains uncertain. Manufacturers propose that small currents alter neurotransmitter levels and shift EEG towards alpha rhythms in brainstem and limbic circuits involved in arousal, mood and pain modulation, and some modelling and imaging work suggests that a portion of the current does reach these deep structures. The reviewers did not find human evidence strong enough to confirm any specific neurochemical pathway. They also pointed out that in conditions like anxiety, insomnia and chronic pain, expectancy and the calming routine of daily device use can produce substantial improvement on their own, which is exactly why sham-controlled designs and successful blinding matter so much when judging these trials.

Limits

A systematic review can only be as good as the trials it finds, and here the trials were mostly small, old, heterogeneous and poorly reported, which is why so many conclusions were insufficient rather than negative. The reviewers could not perform meta-analysis, so effect sizes are not summarised numerically. The search closed in 2017, before the 2023 NHS Alpha-Stim-D trial, which would almost certainly have lowered rather than raised the rating for depression. The review was funded by the VA, which had an interest in the answer but no commercial stake. Its verdict, low-strength evidence for one indication and insufficient for the rest, remains the most balanced independent summary of the field before the Lancet Psychiatry trial.